Shionogi Second Quarter 2025 Earnings: Revenues Beat Expectations
Shionogi (TSE:4507) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥116.4b (down 4.0% from 2Q 2024).
- Net income: JP¥52.5b (up 9.3% from 2Q 2024).
- Profit margin: 45% (up from 40% in 2Q 2024). The increase in margin was driven by lower expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shionogi Revenues Beat Expectations
Revenue exceeded analyst estimates by 2.1%.
Looking ahead, revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are up 4.5% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for Shionogi that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4507
Shionogi
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
Flawless balance sheet, undervalued and pays a dividend.
